Markers of bone formation and resorption in patients with mixed subtype osteosarcoma;Wartość rokownicza markerów kościotworzenia i resorpcji kości u pacjentów z miȩsakiem kościopochodnym

Nowotwory

Volumn 56, Issue 5, 2006, Pages

  Gajewska, Joanna ^a,b   Ambroszkiewicz, Jadwiga ^a   Klepacka, Teresa ^a   Rychłowska Pruszyńska, Magdalena ^a   Laskowska Klita, Teresa ^a  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Bone turnover markers; Mixed subtype osteosarcoma; Osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; C TERMINAL CROSS LINKING TELOPEPTIDE; CISPLATIN; COLLAGEN TYPE 1; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; OSTEOCALCIN; TELOPEPTIDE;

ADOLESCENT; ADULT; ARTICLE; BONE BIOPSY; BONE METABOLISM; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIXED TUMOR; OSSIFICATION; OSTEOLYSIS; OSTEOSARCOMA; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR REGRESSION;

EID: 33845430702     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11: 281-94.
2. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000; Suppl 6:18-29.
3. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implication for diagnosis imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22: 289-331.
4. Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol 1999; 11: 312-9.
5. Seregeni E, Martinetti A, Ferrari L et al. Clinical utility of biochemical marker of bone remodelling in patients with metastases of solid tumors. Q J Nucl Med 2001;5:1-17.
6. Goltzman D. Osteolysis and cancer. J Clin Invest 2001; 107: 1219-20.
7. Demers L.M. Biochemical markers in the menagement of patients with metastatic bone disease. Clin Chem 1999; 45: 1131-2.
8. Marchei P, Santini D, Bianco V et al. Serum ostase in the follow-up of breast cancer patients. Anticancer Res 1995; 15: 2217-2222.
9. Fontana A., Delmas P.D.: Markers of bone turnover in bone metastases. Cancer 2000; 88: 2952-60.
10. Berruti A, Dogliotti L, Gorzegno G et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 240-7.
11. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88: 2919-26.
12. Ambroszkiewicz J, Gajewska J, Laskowska-Klita T et al. Biochemiczne wskazniki procesu resorpcji kosci u dzieci z osteosarcoma. Med Wieku Rozwoj 2004; 8: 225-33.
13. Gajewska J, Ambroszkiewicz J, Rychlowska-Pruszynska M et al. Markery kościotworzenia u dzieci z osteosarcoma. Med Wieku Rozwoj 2004; 8: 235-43.
14. Bertoni F, Bacchini P. Classification of bone tumors. Eur J Radiol 1988; 27: 74-6.
15. Plebani M, Bernardi D, Zaninotto M et al. New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem 1996; 29: 67-72.
16. Alatas F, Alatas O, Metintas M et al. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 2002; 35: 293-6.
17. Jung K, Lein M, Stephan C et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int Cancer 2004; 111: 783-91.
18. Berruti A, Piovesan A, Torta M et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996; 73: 1581-7.
19. Fanburg JC, Rosenberg AE, Weaver DL et al. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. Am J Clin Pathol 1997; 108: 464-73.
20. Nagoya S, Uede T, Wada T et al. Detection of bone-type alkaline phosphatase by monoclonal antibodies reacting with human osteosarcoma-associated antigen. Jpn J Cancer Res 1991; 82: 862-70.
21. Kir Z.O, Oner P, Iyidogan YO et al. Serum prolidase I activity and some bone metabolic markers in patients with breast cancer: in relation to menopausal status. Clin Biochem 2003; 36: 289-94.
22. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61: 993-8.
23. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implication for diagnosis imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22: 289-331.
24. Body JJ, Dumon JC, Gineyts M et al. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997; 75: 408-12.
25. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34: 252-9.
26. Ferrari S, Zolezzi C, Pratelli L et al. Urinary excretion of pyridinium cross-links and serum Osteocalcin levels in patients with primary high-grade osteosarcoma. Calcif Tissue Int 2003; 73: 1-4.